MMRF ASCO Myeloma Update: Live Blog – 1
The MMRF announced the latest advances in myeloma presented at the 2012 ASCO Annual Meeting in Chicago in a teleconference held today at 1pm.
The faculty present for the teleconference included by Dr. Ravi Vij, MD, Washington University School of Medicine, St. Louis, MO and Dr. Todd M. Zimmerman, MD The University of Chicago Medical Center, Chicago IL. The teleconference began with a welcome note and brief about the history of formation of the MMRF and the research efforts here, by Anne Quinn Young.
Dr. Zimmerman spoke first, and quickly rounded up various drugs and clinical trials that were presented at the ASCO. He specifically talked about untreated multiple myeloma and went abstract by abstract explaining the various trials being conducted and the results obtained. He began with the French trial of Carfilzomib plus melphalan and prednisone compared with the Velcade MP regimen. The 92% objective response rate and very good partial response rate of the trial holds promise said Dr. Zimmerman. He went on to explain the results of the CYCLONE trial from the Mayo Clinic Group with Carfilzomib, thalidomide, cyclophosphamide and dexamethasone. He then proceeded with various results of clinical trials involving efficacy of single agents like Carfilzomib and pomalidomide.
Dr. Vij, spoke next and gave updates about monoclonal antibody therapy drug that were presented at the ASCO. Elotuzumab, stole the center stage in this arena. He explained various results of clinical trials involving elotuzumab and Revlimid, as well as other combination investigations. Dr Vij mentioned about single agent responses of new agents in early stage of development, anti CD-38 or daratumumab, anti IL6 or siltuximab, and anti-BCL -2 or obatoclax, which were not very encouraging nevertheless, opened up avenues for further research.
MLN 9708, oral proteasome inhibitor was the other talked about new agent, apart from elotuzumab.
This was followed by the question answer session where in all participants could ask multiple myeloma related question to the faculty present. The questions answer session was dominated by the discussion on remission, maintenance therapy, and use of Revlimid and Velcade.
The conference concluded with stating and reiterating the need for more research, new drugs, and treatments for multiple myeloma.
It was time well spent and would write a more detailed blog later on.